The Cardiovascular and Renal Drugs Advisory Committee voted 9-3 in favor of Alnylam’s patisiran on whether its benefits outweigh its risks for patients with cardiomyopathy induced by transthyretin amyloidosis.
The FDA panel voted 9 to 3 that the benefits of the drug, patisiran, outweigh its risks for treating patients with a type of heart muscle disease, cardiomyopathy, caused by a wild-type or hereditary transthyretin-mediated amyloidosis (ATTR). ATTR, caused by mutations in the transthyretin gene, leads to accumulation of faulty proteins in body organs and tissues that can lead to loss of sensation, heart issues, eye, kidney and thyroid diseases.
Q2 2024 EPS Estimates for Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) Decreased by Analyst themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Equities research analysts at Zacks Research decreased their Q2 2024 earnings estimates for shares of Alnylam Pharmaceuticals in a research note issued on Wednesday, July 19th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn ($1.16) per share for the quarter, down from […]